NCT05028166 2026-03-27Individual Patient Compassionate Use of MirdametinibSpringWorks Therapeutics, Inc.Available
NCT03259633 2020-05-01An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1AstraZenecaApproved for marketing